Abstract It is generally agreed that the upper age limit for heart transplantation is 60 years. However, an increasing number of elderly candidates are accepted for heart transplantation. We retrospectively analyzed our experience with a total of 204 consecutive transplantations, performed in 195 adult patients (9 retransplantations) between March 1987 and September 1993. There were 48 patients older than 60 years (mean 62.9-+ 3), group I (gr I) and 156 patients between 20 and 59 years old (mean 47.5 _+ 8), group II (gr II). The two groups were matched for sex-ratio (female 10_4 vs 14.2%), indications (cardiomyopathy, ischemic, others), and hemodynamic parameters (pulmonary artery pressure, capillary wedge pressure, cardiac index). A ventricular assist device was used in 14 patients as bridge to transplantation in gr II vs 0 to gr I. There were seven early deaths in gr 1 (14.6%) vs 14 in gr II (8.97%, NS). A total of 183 survivors (41 vs 142) have been followed up for 1 month-6.3 years (mean follow-up 20.4_+ 19.3 months in gr I, 35.4_23 in gr II). No patient was lost to follow-up. There were 11 late deaths in gr I vs 16 in gr II. The most common cause was malignancy (n = 4) in gr I and sudden death (n = 9) in gr II, with a significant difference. The actuarial survival was 68.8% in gr 1 vs 88.5% in gr II at 1 year, 43.5% in gr I vs 76.4% in gr II at 5 years. In conclusion, transplanted patients over 60 years of age have a significantly poorer late survival than younger patients, despite similar good early results. Moreover, the causes of late deaths were different in the two groups_ So, heart transplantation in patients over 60 years of age should be carefully considered. [Eur J Cardio-thorac Surg
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Introduction
In the early days, heart transplantation (HTx) was usually reversed for patients under 50 years of age. Improvements, made in both surgical techniques and postoperative treatment, allowed some extension of the indications for HTx. However, before the introduction of cyclosporine, old patients had an unsatisfactory survival rate related to an increased incidence of death from infection, and age over 55 years became a contraindication of cardiac transplantation [4] . With the introduction of new immunosuppressive treatments, the risk of infection and rejection was reduced, particularly in the elderly [2, 10] . Therefore, many patients who would have been excluded as candidates a few years ago are now considered for HTx. If the age for transplant is not well defined [7] , it is generally accepted [1, 4] that the upper limit is 60 years. However, after strict selection, an increasing number of elderly candidates are now accepted for HTx. In our Institution, as in numerous other centers [3, 8, 12] , the age limit has been extended beyond 60 years. With our experience starting in 1987, our followup allows the study of long-term results and the comparison with other teams.
Materials and methods
From January 1987 to August 1993, 250 orthotopic heart transplantations were performed in our Institution. Excluding 46 patients transplanted before the age of 20, generally for complicated congenital heart defects, 204 were studied in two groups: 48 patients over 60 years of age at the time of HTx (group I) and 156 patients between 20 and 59 years old (group II). Each candidate was carefully evaluated in terms of complete history and physical examination, review of all referring information, radiologic and hemodynamic data. We studied and compared the two populations retrospectively to see if the age of recipient influences early and long-term results. Statistically, the Student t-test was used to determine the differences between the groups, and the chi-squared test to assess the significance of differences in event frequency between the two groups. Sigmficant was determined at a probability less than 0.05. The survival was expressed in actuarial terms by Kaplan-Meier analysis and statistical comparison was performed using the the log rank test.
Patients
The mean age was 62.9 _+ 3 years in the first group (range 60-67.4) and 47_5 +_ 8.8 years in the second (range 21-59). The sex ratio was similar in the two groups (female: 10.4% in gr I vs 14.2% in gr II). In etiological terms, there was no difference in the distribution between the two groups ( Table 1 ). The main reason for transplantation was non-obstructive cardiomyopathy (50% gr I vs 53.2% gr II). Ischemic cardiopathy were less frequent, with similar distribution in the two groups (29.2% gr I vs 27.5% gr II). Lastly, in the first group only one retransplantation was performed (2.1%), versus eight (5.1%) in the second group (NS), for chronic rejection or graft degeneration. The risk factors were analyzed in the two groups (Table 2): the most common factor was smoking in group I (23%) and overweight in group II (7.7%). Patients transplanted after 60 years of age were more often exposed to a cardiovascular risk (36) than the younger ones (23, P<0.005). All the patients were in NYHA functional class III or IV before the transplantation. Hemodynamic data were obtained in each patient by right catheterization and ventriculography. The distribution (Table 3) was not significantly different between the two groups concerning the mean pulmonary artery pressure and capillary wedge pressure. Ejection fractions (20.8 % vs 24.3%) and cardiac index (1.79 vs 1.86 1/min per m 2) were low, expressing the low cardiac output and the deterioration of the left ventricular function. Pulmonary resistances were similar in the two groups and compatible with HTx. In 14 cases, the patient required preoperative mechanical support with Abiomed BVS System 5000 as a bridge to transplantation. All these patients were less than 60 years old (group II). The average time of assistance was 4.4 + 3 days, range 1-10 days.
Surgical procedures
The operative procedure used the technique of orthotopic heart transplantation described by Shumway. Study of the operative data showed the single distinctive element between the two groups; the age of donors was significantly different: 42.3 -+ 12.1 years in group I (range 14-67) and 30_6 -+10.7 years in group II (range 11-56), P < 0.005. On the other hand, technical data were similar: cold isehe- To monitor a possible rejection, the patients were followed up by echocardiography and endomyocardial biopsy every week during the 1 st postoperative month and every 2 months thereafter. The treatment varied with the grade of rejection: steroid and antihymocyte globulin for rejection grade I or II, OKT3 (monoclonal antibody) for rejection grade III.
Results

Early results (<30 days)
Hospital mortality was 14.6% in group I (7 patients) versus 8.97% in group II (14 patients), statistically non-significant (P = 0.13). The most common cause of early death ( Table 4) was dysfunction of the graft (left or right ventricle) with a significant difference between the two populations: 10.4% gr I versus 2.56% gr II (P=0.02). Otherwise Table 4 The main cause of early death is graft dysfunction with a significant difference between the two groups, but without difference in the ages of donors The causes of late death were also different for the two populations (Table 5) . In group 1, 11 late deaths were observed versusl6 in group II. If the rate of fatal rejections was similar, sudden deaths were less frequent in group I (two patients) than in group II (nine patients), with a significant difference. Conversely, malignancies were more often observed in patients over 60 years of age (four cases) than in younger ones (one case), with a statistical difference between the two groups_ In the first group, three cases of lung cancer and one case of gastric cancer were encountered. Two of these were treated unsuccessfully by chemotherapy and the others by lobectomy. The average time lapse between transplantation and death was 2 years. In the second group, one case of lung cancer was observed and treated by surgery and chemotherapy. During the followup no case of lymphoproliferative syndrome was observed. The early results were similar in the two groups concerning the hospital mortality (14.6 vs 8.97%). Previous studies [2, 4, 6] have emphasized the good early results of HTx in old recipients with a similar hospital mortality rate. The causes of early death were similar, except the rate of early graft dysfunction, which was higher in patients transplanted after the age of 60 (P = 0.02). Contrary to the global population understudy, no significant difference was found concerning the age of donors in patients transplanted before or after 60 years of age and dead early (38.4 years -30.3 years). Moreover, in each group previous by understudy, the age of donors was not significantly different in early survivors and non-survivors. No significant difference was found concerning the age of donors in the two groups (38,4 years gr I vs 30.3 years gr II). In each group, the age of donors was not significantly different in survivors and non-survivors according to the t-test (0.26 in gr I, 0.35 in gr II). So, there seems to be no connection between the age of donors and early graft dysfunction. The same data have been reported by Wahlers [11] and Luciani [6] . On the other hand, the rate of fatal early rejection was similar in the two groups. Contrary to Rendlund's findings [10], age over 60 years did not contribute towards decreasing the incidence of early rejections.
The analysis of the long-term results shows a quicker decrease in the survival rates of patients transplanted after 60 years of age than in younger patients. If the actuarial survival is similar during the 1st postoperative year, as in other studies [2, 4] , the difference appears at 1 year (68.8 vs 88.5%) and increases rapidly with time (43.5 vs 76.4% at 5 years). Other studies [1, 2, 4, 7, 10] have shown that there is no difference in the actuarial survival between the two populations. However, the mean follow-up is generally shorter than in our analysis (respectively: 22, 20, 12.3, 29 and 12 months), and the age limit in the group of elderly patients transplanted is generally different (respectively: 60, 50, 60, 55 and 55 years). In our study, if the 1-year survival rate for patients over 60 years of age was comparable with that of the younger patients, the 5-year rate was extremely different. Similar data have been published by Copeland [3] , who found an identical survival rate in two groups (+50 years) for the initial 2 years, followed by a significant drop in survival of the older group in the 3rd year. Otherwise, earlier studies [1, 4, 5, 8] included young recipients, even when they were less than 1 year old, which could explain the same survival rate between the two populations. Finally, life expectancy is lower in the elderly in the normal population and this difference persists in candidates for HTx. Moreover, the age of donors seems to be important in each group in terms of the actuarial survival. There is a significant difference concerning the age of donors between longterm survivors and non-survivors in group II (< 60 years, P = 0.026), in contrast to group I (P = 0.16). This influence has been shown by Young [ 12] in a general heart-transplanted population. In our experience, an older donor age seems to influence the actuarial survival in patients less than 60 years of age, but does not alter the long-term results in older patients.
The causes of late deaths were also different. It is generally admitted that the main causes of death after HTx are infection and rejection [2, 4, 9] , but unrelated to the age of the recipient. In our study, sudden deaths were more frequent in patients younger than 60 years and were the main cause of late death in this age group (18 vs 56%); in these cases, the ages of donors were comparable in the two groups (39 years gr I v 35.8 years gr II), eliminating this aspect as a risk factor of mortality. This element could be a determinant of graft degeneration, because graft arteriosclerosis seems to be more frequent in the group of old donors [5, 9] , which was not found in our study. Otherwise, malignancies were the main cause of late death in patients transplanted after 60 years of age and were more often observed in this group than in younger patients (36 vs 6%). A non-cardiac disease undiagnosed during the preoperative screening could be frequent in this age group. These data could explain the deterioration of the long-term results in this group. Malignancies are frequent in the transplanted population (12.8%, [9] ). The role of immunosuppressive therapy is certainly important in the development of malignancies, particularly in this age group. Finally, contrary to Rendlund's findings [10], there was no difference in the rate of rejection in the two groups.
In conclusion, heart transplantation is justified in patients over 60 years of age, if we consider the early results during the 1 st postoperative year. The long-term results observed in this study show that heart transplantation should be considered with care in this age group. The present organ shortage increases the waiting time for transplantation. For these reasons our team favors old donors for recipients over 60 years. Otherwise, non-cardiac diseases are frequent and must be carefully researched during the preoperative screening, as shown by the number of malignancies observed in these patients treated with immunosuppressive therapy. Dr. Robin: No, it is a retrospective study and at the beginning of our experience we did not select older hearts for older patients. However, faced with the present lack of donors, our tendency has been to favor older donors for older recipients.
Dr. Borst: I think it is a rather important element because often you tend to give an older heart to an older patient, which might make the difference.
Dr. M. Loebe (Berlin, Germany): Everyone involved with heart transplantation is well aware that medium-and long-term results in all age groups are presently far from ideal and in need of improvement. We encountered the problem of older recipients in 1989, as presented in our results with those panents to the International Society of Heart Transplantation. At that time, 5-year survival in 41 patients over 55 years of age at the time of transplantation was 55% compared to 65% in 190 patients under the age of 55. These results are quite similar to those presented by Dr. Robin. Since it was our policy to include, rather than exclude, patients from treatment, we sought to improve our results in elderly recipients_ The 4-year survival rate for 49 patients who underwent surgery between 1990-1994 and were older than 60 years at the time of transplantation now reaches 79_6%. This improvement was achieved by modifying immunosuppression based upon immunologic monitoring and avoiding the use of monoclonal antibodies. Additionally, renal function was protected by the use of urodilation, which was particularly helpful in elderly recipients. Infection prophylaxis and dally non-invasive rejection monitoring were the cornerstones for improving survival in high risk transplant recipients.
This leads me to my questions. First, since malignancies were the most frequent cause of death in your group of patients older than 60 years, I would like to ask what the incidence of malignancy was, not only as far as mortality, but also as far as morbidity, was concerned, and how malignancies were treated. Secondly, was there any correlation to the type of immunosuppression you chose? It was our impression that monoclonals dramatically contributed to the occurrence of malignancies.
We strongly suggest that one should accept patients over the age of 60 for heart transplantation. We do not see any reason to exclude patients from the benefit of treatment simply due to advanced age. Therefore my final question is, what is your current policy regarding elderly patients? Dr. Robin: Concerning malignancies observed in patients over 60 years of age, we have encountered three cases of lung cancer and one case of gastric cancer; two of which were treated surgically and two others by chemotherapy_ In group I1, we observed only one case of cancer; it was a lung cancer treated unsuccessfully by chemotherapy. In this study, no case of cancer treated with success was observed. But, since the end of this report, we have encountered two new cases of malignancies: one in a patient over 60: it was a lung cancer treated by lobectomy with 8 months of follow-up, and one lymphoproliferative syndrome in a 48-year-old woman treated by chemotherapy with 9 months of followup. It is the first case of lymphoproliferative syndrome that we have observed in our transplanted population. It might be related to our non-systematic administration of antilymphocyte serum in cases of moderate rejection.
Concerning our immunosuppressive protocol, we use the same treatment in every case because we think that if the protocol is efficient in young patients, it will be satisfactory in older ones. To have a cancer under immunosuppressive treatment is certainly a problem and it is difficult to ascertain the relative influences of age, cancer and immunosuppressive protocol. With later results and new reports we will may be modify our point of view.
Dr. A. Cobanoglu (Portland, Oregon).
This slide summarizes the International Society for Heart and Lung Transplantation survey as far as the effect of certain variables on outcome is concerned and recipient age above 60 is definitely a risk factor as far as 1-year survival is concerned. Actually even recipient age above 50 is a risk factor. The best candidates are those between 5 and 50 years of age.
And, again, in the older patients, those above 65 years of age, there is definitely a drop of the survival curve at about 2-3 years and the curves widen even further a few years down the hne, when this group is compared with the younger patients.
I have a couple of questions for you. The graft dysfunction rate was quite high in the older recipients. Why was this? It is not just older donor age that affects outcomes. It may be that these donors were "high risk" donors or marginal donors on high inotropic support, and you may have accepted them just because your recipient was on the old side age-wise. Was there such a matching process? Did you use marginal, high risk donors in the older recipients? And also how do you explain the higher rate of sudden death in the older recipient group? Did you get autopsies on these patients? Did they have a higher incidence of coronary vasculopathy? Dr. Robin: Regarding the early graft dysfunction, we do not think that we use borderline organs for old patients_ Indeed, we exclude all donors in an unstable hemodynamic condition, under heavy medication or with previous cardiovascular history. We do not remove the heart if we find plaques of cholesterol on the coronary arteries or if the cardioplegic arrest is not immediately obtained. In our study the graft dysfunction was related in some cases to the heart itself and in others to right ventricular failure because of elevated pulmonary resistances. Concerning the sudden deaths observed in patients less than 60 years old, we did not get autopsies. But in some cases the death occurred in patients with coronary disease found at the systematic angiography and waiting for a retransplantation. We think now that these diseases are an indication for retransplantation and we perform a coronarography every year after the transplantation.
